Numeric Investors LLC Has $12.433 Million Position in Pfizer Inc. (PFE)
Numeric Investors LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 71.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 382,800 shares of the biopharmaceutical company’s stock after selling 977,453 shares during the period. Numeric Investors LLC’s holdings in Pfizer were worth $12,433,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in shares of Pfizer during the fourth quarter valued at about $384,874,000. State Street Corp increased its stake in Pfizer by 3.5% in the fourth quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock valued at $10,419,393,000 after buying an additional 10,838,463 shares during the last quarter. Asset Management One Co. Ltd. increased its stake in Pfizer by 618.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,094,592 shares of the biopharmaceutical company’s stock valued at $360,362,000 after buying an additional 9,550,335 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in Pfizer during the fourth quarter valued at $289,666,000. Finally, FMR LLC increased its stake in Pfizer by 22.0% in the fourth quarter. FMR LLC now owns 21,970,338 shares of the biopharmaceutical company’s stock valued at $713,596,000 after buying an additional 3,958,324 shares during the last quarter. 69.53% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) traded up 0.74% on Friday, hitting $32.46. The stock had a trading volume of 28,354,336 shares. Pfizer Inc. has a 12 month low of $29.83 and a 12 month high of $37.39. The firm has a market cap of $193.72 billion, a P/E ratio of 27.32 and a beta of 0.94. The firm’s 50-day moving average price is $33.58 and its 200 day moving average price is $32.89. Pfizer also was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 1,119 put options on the company. This is an increase of approximately 137% compared to the average volume of 473 put options.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The firm’s revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Analysts anticipate that Pfizer Inc. will post $2.55 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 1st. Investors of record on Friday, May 12th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.97%. The ex-dividend date is Wednesday, May 10th. Pfizer’s dividend payout ratio is currently 110.35%.
Several analysts recently weighed in on the company. Piper Jaffray Companies set a $53.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Saturday, January 21st. Sanford C. Bernstein reiterated a “buy” rating and set a $37.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Barclays PLC reiterated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Deutsche Bank AG reiterated a “buy” rating and set a $40.00 target price on shares of Pfizer in a research note on Thursday, February 16th. Finally, Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $34.97 price target on the stock. in a research note on Thursday, February 23rd. One research analyst has rated the stock with a sell rating, ten have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $37.54.
In other Pfizer news, insider Charles H. Hill sold 36,000 shares of Pfizer stock in a transaction dated Thursday, March 9th. The shares were sold at an average price of $34.07, for a total transaction of $1,226,520.00. Following the completion of the transaction, the insider now owns 57,329 shares in the company, valued at $1,953,199.03. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mikael Dolsten sold 30,970 shares of Pfizer stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $34.51, for a total transaction of $1,068,774.70. Following the transaction, the insider now owns 64,719 shares of the company’s stock, valued at approximately $2,233,452.69. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,470 shares of company stock worth $2,449,150. 0.07% of the stock is owned by insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.